Yesterday, an FDA advisory panel recommended 20-1 that GSK’s Avandia remain on the market. The same panel also acknowledged that Avandia does have serious cardiovascular complications. So new warnings, but not a complete withdrawal.
Tuesday, July 31, 2007
And Avandia Stays…For Now
Yesterday, an FDA advisory panel recommended 20-1 that GSK’s Avandia remain on the market. The same panel also acknowledged that Avandia does have serious cardiovascular complications. So new warnings, but not a complete withdrawal.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment